Clinical trial Recruiting at 1 site Phase2; Phase3 Interventional Ages 18 to 100

Transnasal nerve block for headaches after brain hemorrhage

Official title: Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache

Run by University of California, Davis · NCT06621329 · Data updated 2026-11-12

This study is testing if a special nose treatment can help reduce headaches in people who have had a brain hemorrhage and see if it can lower their need for pain medication.

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages18 Years to 100 Years
SexAll
Enrollment40 (estimated)
SponsorUniversity of California, Davis
Academic / other
Locations1 site (Sacramento, California)
StatusRecruiting
StartedOctober 17, 2024
Main results expectedJuly 2027
Study endsOctober 2027
Registry record updatedAugust 18, 2026
Trial IDNCT06621329 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 18 years old with a secured aneurysm and acute subarachnoid hemorrhage who can communicate their pain levels.

Probably not a fit

Patients with unsecured aneurysms, recent nasal or facial trauma, or those who cannot verbalize pain scores may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a transnasal sphenopalatine ganglion (SPG) block in reducing headache severity in patients suffering from acute subarachnoid hemorrhage (aSAH). It involves a randomized controlled design with 40 participants, comparing standard pain medication alone to standard medication combined with the SPG block administered via a needleless device. The study also aims to assess the impact of this intervention on opioid usage during hospitalization and at discharge. Data on pain scores and safety monitoring will be collected over a 24-month period, with individual participation lasting up to four weeks.

Why it matters

Potential benefit: If successful, this approach could significantly reduce headache severity and opioid dependency in patients with acute subarachnoid hemorrhage.

How similar studies have gone: While the use of nerve blocks for headache management is established, this specific approach using a transnasal SPG block is novel and has not been extensively tested in this context.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Acute subarachnoid hemorrhage
* Age greater than 18 years
* Secured aneurysm
* Patient can verbalize pain score to clinician, nurse, medical translator, or surrogate decision
* maker
* Patient or surrogate decision maker is available to consent

Exclusion Criteria:

* Less than 18 years old
* Unsecured aneurysm
* Pregnant or lactating
* Prisoner
* Unable to verbalize pain score to clinician, nurse, medical translator, or surrogate decision maker
* Nasal or facial trauma or surgery within the last three months
* Allergy to lidocaine, bupivacaine, or dexamethasone
* Patient is unable to consent and no available surrogate decision maker

Where it's running

  • UC Davis Medical Center
    Sacramento, California, United States
    Recruiting

Study contacts

  • Principal investigator: Christine Picinich, MS, AGACNP-BC, CCRN — University of California, Davis
  • Study coordinator: Janice Wang-Polagruto, PhD, CCRP
  • Email: jfwang@ucdavis.edu
  • Phone: 916-551-3244

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.